These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17407651)

  • 1. Oral antidiabetic agents in type 2 diabetes.
    Levetan C
    Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
    Hermansen K; Mortensen LS
    Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
    Umetsu R; Nishibata Y; Abe J; Suzuki Y; Hara H; Nagasawa H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2014; 134(2):299-304. PubMed ID: 24492232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes and oral antihyperglycemic drugs.
    Mizuno CS; Chittiboyina AG; Kurtz TW; Pershadsingh HA; Avery MA
    Curr Med Chem; 2008; 15(1):61-74. PubMed ID: 18220763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
    Barnett A; Allsworth J; Jameson K; Mann R
    Curr Med Res Opin; 2007 Jul; 23(7):1493-507. PubMed ID: 17559747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
    Meece J
    Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
    Purnell JQ; Weyer C
    Treat Endocrinol; 2003; 2(1):33-47. PubMed ID: 15871553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
    Mori Y
    Nihon Rinsho; 2011 Aug; 69(8):1505-14. PubMed ID: 21838054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
    Azim S; Baker WL; White WB
    Curr Cardiol Rep; 2014 Nov; 16(11):541. PubMed ID: 25303895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current and future aspects of oral antidiabetic agents in type 2 diabetes].
    Rybka J
    Vnitr Lek; 2001 May; 47(5):285-90. PubMed ID: 11395869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.